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Classic Hodgkin’s lymphoma (HL) tissue contains a
small population of morphologically distinct malignant
cells called Hodgkin and Reed-Sternberg (HRS) cells,
associated with the development of HL. Using 3-rapid
amplification of cDNA ends (RACE) we identified an
alternative mRNA for the DEC-205 multilectin receptor
in the HRS cell line L428. Sequence analysis revealed
that the mRNA encodes a fusion protein between DEC-
205 and a novel C-type lectin DCL-1. Although the 7.5-kb
DEC-205 and 4.2-kb DCL-1 mRNA were expressed inde-
pendently in myeloid and B lymphoid cell lines, the
DEC-205/DCL-1 fusion mRNA (9.5 kb) predominated in
the HRS cell lines (L428, KM-H2, and HDLM-2). The DEC-
205 and DCL-1 genes comprising 35 and 6 exons, respec-
tively, are juxtaposed on chromosome band 2q24 and
separated by only 5.4 kb. We determined the DCL-1 tran-
scription initiation site within the intervening sequence
by 5-RACE, confirming that DCL-1 is an independent
gene. Two DEC-205/DCL-1 fusion mRNA variants may
result from cotranscription of DEC-205 and DCL-1, fol-
lowed by splicing DEC-205 exon 35 or 34–35 along with
DCL-1 exon 1. The resulting reading frames encode the
DEC-205 ectodomain plus the DCL-1 ectodomain, the
transmembrane, and the cytoplasmic domain. Using
DCL-1 cytoplasmic domain-specific polyclonal and DEC-
205 monoclonal antibodies for immunoprecipitation/
Western blot analysis, we showed that the fusion mRNA
is translated into a DEC-205/DCL-1 fusion protein, ex-
pressed in the HRS cell lines. These results imply an
unusual transcriptional control mechanism in HRS
cells, which cotranscribe an mRNA containing DEC-205
and DCL-1 prior to generating the intergenically spliced
mRNA to produce a DEC-205/DCL-1 fusion protein.
Classic Hodgkin’s lymphoma (HL)1 is a common malignant
lymphoma characterized by the presence of a small population
(1%) of putative malignant cells, the morphologically distinct
Hodgkin and Reed-Sternberg (HRS) cells. Recent advances in
cell isolation techniques and molecular biology has identified Ig
gene rearrangements within the majority of individual HRS
cells, suggesting their B cell origin (1). These are surrounded by
a large population of apparently non-malignant lymphocytes
and histiocytes, whose proliferation is likely to be mediated by
the wide range of cytokines and chemokines released by the
HRS cells (reviewed in Refs. 2 and 3).
HRS cells have many characteristics in common with anti-
gen-presenting cells (APCs) such as activated B cells and den-
dritic cells (DCs) (4). Indeed, the HRS cell lines (L428,
HDLM-2, and/or KM-H2) express cell surface molecules re-
quired for costimulation/proliferation of T cells (major histo-
compatibility complex class II, CD40, CD80, and CD86) (5–7),
cell adhesion molecules involved in DC-T cell interactions
(LFA-1, CD11c, and ICAM-1–3) (8, 9), and the DC-associated
molecules (CD83 and fascin) (6, 10). They also produce inflam-
matory cytokines (e.g. tumor necrosis factor- and lympho-
toxin) (11), non-inflammatory cytokines (e.g. granulocyte mac-
rophage-colony stimulating factor and interleukins 5 and 13)
(12, 13), and chemokines (e.g. TARC) (14), which are associated
with APCs. L428 cells have been used successfully in our lab-
oratory to produce monoclonal antibodies (mAb) against DC
differentiation antigens such as CMRF-44 (15) and CMRF-56
(16) and to clone the DC-associated molecules such as DEC-205
type I transmembrane multilectin receptor (17) and the adeno-
sylhomocysteine hydrolase-like molecule DCAL/AHCYL-1 (18).
We have investigated cell surface molecules on HRS cell lines
with a view to identifying novel molecules related to APC
function. These molecules might also be candidate targets for
antibody-based HL immunotherapy. Indeed, CD20, CD25, and
CD30 reagents (markers for B cells and activated lymphocytes)
have been investigated in this regard (19–21), but molecules
more restricted to HRS cells might be preferred as targets for
more specific therapeutics.
During the cloning of DEC-205 from the L428 cell line by
3-rapid amplification of cDNA ends (RACE) (17), we discov-
ered an alternatively spliced novel DEC-205 mRNA. This
mRNA encodes the intact DEC-205 ectodomain but included
unique sequences encoding for an additional carbohydrate rec-
ognition domain (CRD) and a transmembrane (TM) and a cy-
toplasmic (CP) domain derived from a newly identified type I
transmembrane C-type lectin DCL-1. A partial cDNA sequence
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(KIAA0022) of DCL-1 was identified by random sequencing of a
KG-1 cDNA library (22). Here, we describe the characterization
of the DEC-205/DCL-1 fusion mRNA and protein. Its appar-
ently selective expression in HRS cells may make it a useful
target for both antibody- and T cell-mediated immunotherapy.
EXPERIMENTAL PROCEDURES
Cell Lines—The human hematopoietic cell lines, HEL, KG-1, K562,
THP-1, U937, Mann, Daudi, Raji, WT49, Mann, Molt-4, Jurkat, HL-60,
and HSB-2 were obtained from the American Type Culture Collection
(Rockville, MD). L428 cells were provided by V. Diehl (Klinik fur Innere
Medizin, Cologne, Germany) (23). HDLM-2 (24) and KM-H2 cells (25)
were obtained from the German Collection of Microorganism and Cell
Culture (Braunschweig, Germany). Mono Mac 6 cells (26) were pro-
vided by E. M. Schneider (Dusseldorf, Germany). All cell lines were
maintained in RPMI 1640 (Invitrogen, Melbourne, Victoria, Australia),
10% (v/v) fetal calf serum (Invitrogen), 100 units/ml penicillin, and 100
g/ml streptomycin, except for HDLM-2 cells, which were maintained
in 20% (v/v) fetal calf serum. These cells were subjected to RNA prep-
aration using TRIzol (Invitrogen) for RT-PCR and Northern blot
analysis.
Antibodies and Other Reagents—The mAb MMRI-7 against human
DEC-205 was produced in our laboratory (27). MMRI-7 binds to an
epitope within DEC-205 CRDs 1 and 2. The other anti-human DEC-205
mAb, M335, was provided by R. J. Armitage (Immunex, Seattle, WA)
through the 7th International Workshop on Human Leukocyte Differ-
entiation Antigens. M335 binds to an epitope within DEC-205 cysteine-
rich domain (27).
Goat anti-mouse IgG was purchased from Dako (Botany, New South
Wales, NSW, Australia). Horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG-Fc-specific and protein A-conjugated agarose
beads were from Sigma (Castle Hill, NSW, Australia). HRP-conjugated
sheep anti-rabbit IgG was from Silenus (Melbourne, Victoria, Austra-
lia). ELISA plates (Maxsorb) were from Nalge Nunc International
(Rochester, NY). Prestained protein standards (Benchmark Prestained
Protein Ladder) and DNA ladder (1-kb ladder) were from Invitrogen.
Molecular biological enzymes (e.g. restriction enzymes, polymerases,
and ligase) were obtained from Invitrogen, Promega (Sydney, NSW,
Australia) or Roche Applied Science (Castle Hill, NSW, Australia).
Unless specified, general chemicals were obtained from Sigma or BDH
(Poole, England).
Rabbit polyclonal peptide antisera against the DEC-205 CP domain
and the DCL-1 CP were produced by immunizing New Zealand White
rabbits with diphtheria toxoid-conjugated synthetic peptide CEDEIM-
LPSFHD and CGEENEYPYQFD (Minotopes, Clayton, Victoria, Aus-
tralia), respectively, using a conventional schedule with Freund adju-
vant at the Herston Medical Research Institute (Herston, Queensland,
Australia). To assess the titer of the antibodies against CP peptides, an
ELISA plate was coated with streptavidin (Sigma) and biotinylated
peptides for DEC-205 CP (biotin-SGSGEDEIMLPSFHD) and DCL-1
CP (biotin-SGSGEENEYPYQFD) captured. The plate was blocked with
1% (w/v) sodium caseinate (Sigma) in PBS and 0.1% (w/v) Tween 20
(PBS/Tween) and incubated with serially diluted antisera. After wash-
ing the plate with PBS/Tween, bound antibody was detected with HRP-
sheep anti-rabbit IgG and o-phenylenediamine hydrochloride and quan-
titated with 492 nm using an ELISA reader. There was no cross-
reactivity detected between these two rabbit CP antibodies at the
dilutions used in the experiments described (data not shown).
3-Rapid Amplification of cDNA Ends—The 3-end of DEC-205
mRNA was obtained by 3-RACE, which was performed as described
previously (17). Briefly, L428 mRNA was reverse-transcribed with an
oligo(dT) adaptor primer. The obtained L428 cDNA pool was subjected
to PCR using a DEC-205-specific forward primer and an adaptor primer
and cloned into pBluescript SKII (Stratagene, La Jolla, CA). The clones
were analyzed by restriction enzyme mapping and sequencing using a
BigDye Terminator kit on an ABI Prism 377 automated sequencer (PE
Applied Biosystems, Scoresby, Victoria, Australia) by Australian Ge-
nome Research Facility (University of Queensland, St. Lucia, Queens-
land, Australia).
RT-PCR Analysis—PCR was performed on the L428 cDNA pool using
DEC-205-specific forward primers (078, 088, 090, 092, and 094, nested
within various parts of the DEC-205 ectodomain) in combination with
either DEC-205-specific reverse primer (085, nested within DEC-205
CP) or DCL-1-specific reverse primer (086, nested within DCL-1 ectodo-
main) with an Expand Long Template PCR system (Roche Applied
Science) (Table I). The PCR reactions were fractionated in 0.8% (w/v)
agarose in Tris acetate buffer (40 mM Tris acetate, 1 mM EDTA, pH 7.6)
and visualized with ethidium bromide. The PCR products obtained by
the primer combination 078/085 and 078/086 were cloned into pGEM-T
Easy vector (Promega) and sequenced.
Northern Blot Analysis—Approximately 10 g of total RNA from
cultured cell lines was fractionated in formaldehyde-denatured 1%
(w/v) agarose gel and transferred to a Hybond N cationic nylon mem-
brane (Amersham Biosciences, Sydney, NSW, Australia). The 864-bp
DEC-205 cDNA probe nested within DEC-205 CRD1 and -2 was PCR-
amplified using primers 094 and 095 on the DEC-205 cDNA clone
pCRD1/2-Ig (27) and Taq polymerase (Roche Applied Science). The
1617-bp DCL-1 cDNA probe was PCR-amplified using DCL-1-specific
primers 062 and 063 on the pBS30-1 (Fig. 1). These probes were puri-
fied using a QIAquick PCR purification kit (Qiagen, Clifton Hill, Victo-
ria, Australia) and labeled with [-32P]dATP (Amersham Biosciences)
using a Strip-EZ DNA StipAble DNA probe Synthesis and Removal kit
(Ambion, Austin, TX). The membrane was hybridized sequentially with
these probes and exposed to a Kodak BioMax MS x-ray film at 70 °C
using an intensifying screen (Amersham Biosciences). The final wash
was 0.1  SSC (1  SSC is 0.15 M NaCl, 15 mM sodium citrate, pH 7.0)
and 0.5% (w/v) SDS at 68 °C. After each probing, the membrane was
chemically stripped according to the manufacture’s instructions and
used for hybridization with the other probes.
5-RACE—RNA ligase-mediated 5-RACE was performed using a
FirstChoice RLM-RACE kit (Ambion). Briefly, total RNA from HL-60
was treated sequentially with calf intestinal alkaline phosphatase and
tobacco acid pyrophosphatase to select and to remove the cap structure
of full-length mRNA. The RNA adaptor was ligated to the RNA using T4
RNA ligase, and the RNA was subjected to cDNA synthesis with ran-
dom decamer or DCL-1-specific primer 061 and Thermoscript reverse
transcriptase (Invitrogen). The cDNA was subjected to two rounds of
PCR using DCL-1-specific primers 086 and 099 in combination with the
5-RACE outer primer and inner primer (provided by the kit), respec-
tively. The PCR product was cloned into pGEM-T Easy vector and
sequenced.
Preparation of Cell Lysate—Approximately 107 cells were lysed with
1 ml of 0.15 M NaCl, 25 mM Tris-HCl, pH 7.4, 1% (v/v) Triton X-100,
0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, and a mixture of
protease inhibitors (Complete, EDTA-free, Roche Applied Science) and
incubated on ice for 10 min with occasional vortexing. After centrifu-
gation at 12,000  g for 20 min at 4 °C, the supernatant was collected
and used directly for immunoprecipitation/Western blotting or sand-
wich ELISA analysis described below.
Immunoprecipitation/Western Blot Analysis—The cell extract was
TABLE I
The DNA sequences of oligonucleotides primers used in this study
Primer Sequence (533) Accession number Position (orientation)
061 CATCTGGGCCTTTCCATTGCT AY314007 286–306 (reverse)
062 GACCATGGAGCGGACATGATA AY314007 216–236 (forward)
063 GGCTCTACCATCTGGGTTTGT AY314007 1811–1831 (forward)
078 GAAATGGTTGACTACAAAGAAGA AF011333 4200–4222 (forward)
085 ACCAAATCAGTCCGCCCATGAGAA AF011333 5095–5118 (reverse)
086 ATCATGTCCGCTCCATGGTCAGTA AY314007 212–235 (reverse)
088 TATTCAGAAGTTAAAAGCAGA AF011333 3327–3347 (forward)
090 CCAAAAGGCCGTACTCCAAAA AF011333 2430–2450 (forward)
092 GGAGGAAAACTGAATGACGCA AF011333 1518–1538 (forward)
094 GAAAACGGTTGTGAAGATAAT AF011333 690–710 (forward)
199 GCTCCATGGTCAGTACACTGA AY314007 206–226 (reverse)
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precleared with a non-immune rabbit serum and protein A-Sepharose
(Sigma) for 1 h at 4 °C and subjected to immunoprecipitation using the
rabbit peptide antisera against DEC-205 CP or DCL-1 CP with protein
A-Sepharose overnight at 4 °C. The beads were washed with a wash
buffer (0.15 M NaCl, 25 mM Tris-HCl, pH 7.5, 0.2% (v/v) Triton X-100,
and 0.5% (w/v) sodium deoxycholate), and eluted with SDS-PAGE sam-
ple buffer (2% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.8, 0.01% (w/v) brom-
phenol blue, and 10% (v/v) glycerol) by heating at 95 °C for 5 min. The
samples were subjected to Laemmli discontinuous SDS-PAGE with 10%
(v/v) polyacrylamide separating gel (28) in the non-reducing condition
and transferred to a polyvinylidene fluoride membrane (PVDF-Plus,
Osmonics, Westborough, MA). The membrane was blocked with 5%
(w/v) nonfat dry milk in PBS/Tween (BLOTTO), incubated with a mix-
ture of DEC-205 mAbs (MMRI-7 and M335, 5 g/ml each) overnight at
4 °C, and washed with PBS/Tween. The membrane was incubated with
HRP-anti-goat mouse IgG, and the bound enzyme was detected with
enhanced chemiluminescence (SuperSignal West Pico, Pierce, Rock-
ford, IL) on a Kodak X-Omat XB-1 x-ray film.
Sandwich ELISA—An ELISA plate was coated with 10 g/ml goat
anti-mouse IgG in PBS, washed with PBS/Tween, and blocked with
BLOTTO. To the plate a mixture of DEC-205 mAb (MMRI-7 and M335,
2 g/ml each) was added and incubated for 1 h at room temperature.
The plate was washed and incubated with the serially diluted cell
extracts overnight at 4 °C. The plate was washed with PBS/Tween and
incubated with either rabbit peptide antibodies against DEC-205 CP or
DCL-1 CP (1:1000 dilution in PBS/Tween) or non-immune rabbit serum
for 1 h at room temperature, and, after washing with PBS/Tween, the
plate was incubated with HRP-conjugated goat anti-rabbit IgG in 5%
mouse serum and PBS/Tween. The plate was developed with o-phe-
nylenediamine dihydrochloride and quantitated at 492 nm.
RESULTS
Identification of the cDNA Clone Encoding DEC-205/DCL-1
Fusion—To obtain the 3-end of human DEC-205 mRNA, we
performed 3-RACE (17). This resulted in amplification of a
PCR product of 3 kb (data not shown). When we cloned the
PCR product and analyzed several clones by restriction enzyme
analysis, however, we realized that there were two distinct
sequences within the PCR product. The clone pB30-3 contained
the authentic DEC-205 sequence encoding the DEC-205 CRD
8–10, TM, and CP (17). The other clone pB30-1, however,
encoded DEC-205 CRD 8–10 followed by a unique sequence
distinct from the DEC-205 TM and CP sequence (Fig. 1A). The
junction of the DEC-205 and unique sequence was located
within the connecting region (spacer 11) between the DEC-205
CRD10 and TM. A BLAST search identified the unique se-
quence as a part of the cDNA, KIAA0022 derived from KG-1
cell cDNA library (22). Our further analysis showed that the
KIAA0022 contained a partial cDNA encoding a novel type I
transmembrane C-type lectin receptor, and we termed it DCL-1
(DEC-205-associated C-type Lectin-1). The complete DCL-1
coding region encodes a signal peptide (SP), one CRD, one TM,
and one CP. The KIAA0022 cDNA was recently annotated to a
C-type lectin molecule (GenBankTM accession number
BAA03498), and its gene was mapped to chromosome band
2q24. More details of DCL-1 will be published elsewhere.2
The sequence analysis of the clone pB30-1 showed that fu-
sion junction occurred within the codon G/GC (“/” indicates the
junction) for Gly in the DEC-205 spacer 11, connected to the
codon G/AC for Asp in the junction between the DCL-1 SP and
CRD. The fusion junction was in-frame, connecting the DEC-
205 CRD 10 to the DCL-1 CRD, TM, and CP, suggesting that
the DEC-205/DCL-1 fusion mRNA is translated. Furthermore,
analysis of the DEC-205 and DCL-1 genes indicated that for
this fusion mRNA the junction is formed by splicing DEC-205
exon 35 and DCL-1 exon 1, resulting in the fusion of DEC-205
exon 34 to DCL-1 exon 2 (a variant fusion mRNA termed V34-2,
Fig. 1B). An additional variant fusion mRNA termed V33-2 is
described below.
The DEC-205/DCL-1 Fusion mRNA Appears to Encode the
Entire DEC-205 Ectodomain—We examined the L428 cDNA
pool containing the DEC-205/DCL-1 junction by RT-PCR to
examine whether it included the entire DEC-205 ectodomain
(Fig. 2). The combination of the DEC-205 CP-specific reverse
primer 085 with DEC-205-specific forward primers, nested to
various parts of DEC-205 ectodomain, yielded major PCR prod-
ucts of the sizes predicted in accordance with the primer com-
binations used. We also detected slightly smaller (by 200 bp)
minor PCR products, which were most apparent in the primer
combinations of 078/085 and 088/085. When the DCL-1-specific
reverse primer 086 was used in combination with the same
DEC-205-specific forward primers, we detected doublet bands
(200 bp apart), the larger band of which was the predicted
size. Sequence analysis indicated that the smaller RT-PCR
fragments from DEC-205 itself or the DEC-205/DCL-1 fusion
mRNA were amplified from alternatively spliced RNA, lacking
2 S. Khan, K. J. McDonald, B. P. O’Neill, N. Gonzalez, B. J. Cooper, D.
N. J. Hart, and M. Kato, manuscript in preparation.
FIG. 1. Identification of the cDNA clone encoding DEC-205/
DCL-1 fusion. A, a schematic presentation of DEC-205 mRNA (top,
partial structure) and two representative clones (pB30-3 and pB30-1)
isolated from the DEC-205 3-RACE product. The boxes in the DEC-205
mRNA indicate domain structures, including carbohydrate recognition
domains (CRDs), a transmembrane domain (TM), and a cytoplasmic
domain (CP). Wide black bars indicate the DNA sequence for DEC-205
(17), and wide shaded bars indicate the DNA sequence for the novel
C-type lectin DCL-1 (KIAA0022) (22). The broken line indicates the
position of the junction between DEC-205 and DCL-1. B, the DNA and
corresponding amino acid sequences adjacent to the junctions for two
variants of DEC-205/DCL-1 fusion proteins. Top two sequences show
DEC-205 sequences adjacent to the fusion junctions for DEC-205/
DCL-1 fusion protein variants V34-2 and V33-2, respectively. The third
sequence shows that the DCL-1 sequence adjacent to the fusion junc-
tion. The bottom two sequences show DEC-205/DCL-1 fusion variants
V34-2 and V33-2 produced by DEC-205 exon 34 fused to DCL-1 exon 2
and DEC-205 exon 33 fused to DCL-1 exon 2, respectively. An arrow
indicates the DEC-205/DCL-1 junction, apparent after gene analysis
was performed to assign the exon-intron junction of DEC-205 and
DCL-1 gene. SP, signal peptide.
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DEC-205 exon 34 (168 bp, described below). Thus, L428 cells
express at least two variants of the DEC-205/DCL-1 fusion
mRNAs, one with DEC-205 exon 34 fused to DCL-1 exon 2 (a
variant termed V34-2) and one with DEC-205 exon 33 fused to
DCL-1 exon 2 (a variant termed V33-2) (Fig. 2). Sequence
analysis of the fusion junction of V33-2 showed that the junc-
tion is in-frame, indicating that V33-2 DEC-205/DCL-1 fusion
mRNA is also likely to be translated. The V34-2 encodes the
entire DEC-205 ectodomain fused to DCL-1 CRD, TM, and CP.
The V33-2 lacks approximately one-third of the C-terminal
portion of DEC-205 CRD 10, and the rest of DEC-205 ectodo-
main is fused to DCL-1.
The DEC-205/DCL-1 Fusion mRNA Is Predominantly Ex-
pressed by HRS Cell Lines—To assess DEC-205/DCL-1 fusion
mRNA expression, we performed Northern blot analysis in
several hematopoietic cell lines (Fig. 3). The DCL-1-specific
probe nested within the DCL-1 ectodomain detected a single
4.2-kb DCL-1 mRNA band in myeloid cell lines (HEL, HL60,
U937, and Monomac 6), but no bands were detected in the B or
T cell lines tested. We detected a single 9.5-kb DEC-205/DCL-1
mRNA band in HRS cell lines (HDLM-2, L428, and KM-H2),
however, we did not detect the 4.2-kb DCL-1 mRNA band
observed in the myeloid cell lines. The U937 cells appear to
express a small amount of the 9.5-kb DEC-205/DCL-1 mRNA in
addition to the 4.2-kb DCL-1 mRNA band. When the DEC-205-
specific probe nested within the cysteine-rich domain was used
to hybridize the same blot after the DCL-1 probe was stripped,
a 7.5-kb DEC-205 mRNA band was detected in myeloid cell
lines (HEL and U937), B cell lines (Daudi and Mann), and all
HRS cell lines. In addition, we detected a 9.5-kb DEC-205/
DCL-1 mRNA band in all HRS cell lines and the U937 as
described previously (17). Thus, it appears that the DEC-205/
DCL-1 fusion mRNA predominates in HRS cell lines.
The DEC-205 and DCL-1 Genes Are Juxtaposed in Chromo-
some Band 2q24—We mapped the DEC-205 gene (LY75) pre-
viously to the chromosome band 2q24 (17). The KIAA0022/
DCL-1 gene was previously located to chromosome 2 (22) and
further mapped recently to the identical chromosomal band in
the NCBI UniGene data base. Using the NCBI Genome
BLAST, we identified the human genomic contig NT 005151
containing both DEC-205 and the DCL-1 gene. Our sequence
analysis showed that DEC-205 and DCL-1 genes consist of 35
and 6 exons, respectively, and the DEC-205 gene is localized
5.4 kb upstream of the DCL-1 gene (Fig. 4).
The DCL-1 Gene Is Independently Expressed from the DEC-
205 Gene—It is possible that the proposed DCL-1 gene is a part
of DEC-205 gene and that the DCL-1 mRNA is generated by
alternative splicing of DEC-205 mRNA driven by DEC-205
promoter. If this were the case, the DCL-1 5-untranslated
region should contain at least some DEC-205 gene sequences.
To assess this possibility, we performed RNA ligase-mediated
5-RACE using HL-60 total RNA and determined the DCL-1
transcription initiation site (Fig. 5). This procedure is designed
to amplify cDNA only from full-length, capped mRNA, and
suitable to determine the transcription initiation site. Two
rounds of DCL-1-specific PCR amplification of the DCL-1 cDNA
yielded a 250-bp single band regardless of primers (random
decamers or DCL-1-specific primer 061) for reverse transcrip-
tion (Fig. 5A). Sequencing of the 5-RACE product indicated
that DCL-1 transcription initiation site is mapped to 44 bp
upstream of DCL-1 translation start codon (ATG, A at 1)
located within the 5.4-kb intervening sequence between DEC-
205 and DCL-1 gene. Thus, the DCL-1 gene is transcribed
independently from DEC-205 gene.
Therefore, the DEC-205 and DCL-1 fusion mRNA variants
appear to be generated by cotranscription of both DEC-205 and
FIG. 2. The DEC-205/DCL-1 fusion mRNA encodes the entire
DEC-205 ectodomain. The L428 cDNA was subjected to RT-PCR
using either a DEC-205-specific reverse primer (085) or a DCL-1-spe-
cific reverse primer (086) in combination with various DEC-205-specific
forward primers (078, 088, 090, 092, and 094) and fractionated with
0.8% (w/v) agarose gel electrophoresis. The positions of these gene-
specific primers are indicated as arrows in the schematic diagram
(bottom). The doublets obtained with several sets of primer combina-
tions correspond to alternatively spliced DEC-205 mRNA (see text). SP,
signal peptide; CR, cysteine-rich domain; FN, fibronectin type II do-
main; CRD, carbohydrate recognition domain; TM, transmembrane
domain; CP, cytoplasmic domain.
FIG. 3. The DEC-205/DCL-1 fusion mRNA is predominantly ex-
pressed by HRS cell lines. Total RNA from hematopoietic cell lines
was subjected to Northern blot analysis, probed sequentially with the
DCL-1 (top panel) and DEC-205 (middle panel). The bottom panel
shows methylene blue staining of 28 S ribosomal RNA. The arrowheads
indicate the positions of 9.5-kb DEC-205/DCL-1 fusion mRNA detected
by both DCL-1 (top panel) and DEC-205 probes (middle panel). The
asterisks indicate the positions of nonspecific signals caused by the
nonspecific binding of DCL-1 probe to 28 S RNA.
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DCL-1 genes followed by intergenic splicing to remove the
DEC-205 exon 35 alone or exon 34–35 along with DCL-1 exon
1, resulting in DEC-205 exon 34 fused to DCL-1 exon 2 (V34-2)
or DEC-205 exon 33 fused to DCL-1 exon 2 (V33-2) (see Fig. 1).
The DNA sequences of DEC-205/DCL-1 fusion mRNA variants
and DCL-1 mRNA were submitted to the GenBankTM and
assigned the accession number AY184222 (for V34-2),
AY314006 (for V33-2), and AY314007 (for DCL-1), respectively.
DEC-205/DCL-1 Fusion mRNA Is Translated to the Fusion
Protein—We sought to establish whether the DEC-205/DCL-1
fusion mRNA is translated into a fusion protein. We prepared
cell lysates from three HRS cell lines (DEC-205 mRNA and
DEC-205/DCL-1 fusion mRNA), HEL (DEC-205 mRNA and
DEC-205/DCL-1 fusion mRNA), and Jurkat cell line (DEC-
205 mRNA and DEC-205/DCL-1 fusion mRNA) (see Fig. 3)
and subjected them to immunoprecipitation with the DEC-205
CP or DCL-1 CP peptide antisera. The immunoprecipitated
samples were further analyzed by Western blot with a mixture
of DEC-205 mAbs (MMRI-7 and M335, both react to the N-
terminal portion of DEC-205) to detect the DEC-205 and DEC-
205/DCL-1 fusion proteins in non-reducing conditions (Fig. 6A).
The DEC-205 CP antiserum precipitated a broad but single
180-kDa DEC-205 protein band specifically from the three
HRS cell lines (L428, HDLM-2, and KM-H2) and HEL cells.
There was no detectable signal in Jurkat cells as expected.
When the DCL-1 CP antiserum was used for the initial immu-
noprecipitation, we detected low levels of the 180-kDa DEC-
205/DCL-1 fusion protein band in the three HRS cell lines, but
not in HEL or Jurkat cells, consistent with the expression of
DEC-205/DCL-1 mRNA in these cell lines (see Fig. 3). The
presence of this DEC-205/DCL-1 fusion protein band in these
HRS cell extracts was not due to cross-reactivity of DCL-1 CP
antiserum with DEC-205 CP, because (i) there was no cross-
reactivity in the DCL-1 CP antiserum with DEC-205 CP pep-
tide assessed by ELISA analysis (data not shown), (ii) 60 times
longer exposure of HEL sample did not produce any band (Fig.
5A), and (iii) the DCL-1 CP antiserum detected the weakest
signal in KM-H2 extracts, which contained most DEC-205 pro-
tein (Fig. 5A and described below). Reversibly, we were also
able to detect DEC-205/DCL-1 fusion protein bands in HRS cell
lines by immunoprecipitation with DEC-205 mAbs and protein
G-conjugated beads and Western blot analysis with DCL-1 CP
antiserum (data not shown).
To determine the relative abundance of the DEC-205/DCL-1
fusion protein to DEC-205, we developed a sandwich ELISA
using the DEC-205 mAbs for capturing and the CP antisera for
detection (Fig. 6B). The HRS cell lines express most DEC-205
protein (KM-H2  L428  HDLM-2), followed by HEL cells.
We detected relatively small amounts of the DEC-205/DCL-1
fusion protein in L428 and HDLM-2 cells, 30–50 times less
than the amount of DEC-205. No fusion protein was detected in
the KM-H2 cells, probably because the amount of KM-H2 de-
rived fusion protein is below the detection limit. The negative
control, Jurkat, did not show any signal. The relative abun-
dance of both DEC-205 and DEC-205/DCL-1 fusion protein by
the ELISA correlated with the immunoprecipitation/Western
blot data (Fig. 6A).
DISCUSSION
Cotranscription and intergenic splicing is a rare event in
mammalian cells, and there are only a small number of reports
describing the presence of fusion mRNA. These include MDS/
FIG. 4. The DEC-205 and DCL-1
genes are juxtaposed in chromosome
band 2q24. A schematic drawing of DEC-
205 (partial) and DCL-1 mRNA (top),
DEC-205 (partial), and DCL-1 genes on
chromosome 2q24 (middle) and DEC-205/
DCL-1 fusion mRNA (V34-2, bottom). In
the top and bottom drawings, boxes indi-
cate domain structures (please see keys in
Fig. 2). In the middle panel, boxes indicate
exons. The drawing of DEC-205/DCL-1
fusion protein variant V33-2 is omitted
for clarity.
FIG. 5. The DCL-1 gene is independently expressed from the DEC-205 gene. Total RNA from HL-60 cells was subjected to RNA
ligase-mediated 5-RACE after being reverse-transcribed with random decamer (d(N)10) or DCL-1-specific primer 061. A, the 5-RACE product was
fractionated with 2% agarose gel and stained with ethidium bromide. B, DNA sequence analysis of the DCL-1 transcription site. The 5-RACE
product was cloned and sequenced. The lowercase letters indicate the genomic DNA sequence upstream of DCL-1 translation start codon (ATG,
boxed). A kinked arrow indicates the position for DCL-1 transcription initiation site. Arrows indicate the positions for DCL-1-specific primers (086
and 199) for two rounds of 5-RACE amplification.
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EVI1 (29), galactose-1-phosphate uridylyltransferase, and in-
terleukin-11 receptor genes (30), Prnd/Prnp (31) and P2Y1/
SSF1 (32). None of these reports, however, examined whether
the fusion mRNA is translated endogenously into cognate fu-
sion protein. Here we describe another cotranscription and
intergenic splicing of two juxtaposed genes, encoding two type
I transmembrane C-type lectin receptors DEC-205 and DCL-1,
respectively. Furthermore, we demonstrated for the first time
to our knowledge that the fusion mRNA is translated endog-
enously into the DEC-205/DCL-1 fusion protein.
DEC-205 is a putative antigen uptake receptor expressed on
dendritic cells (17, 33) and potent APCs, which initiate and
direct immune responses (reviewed in Refs. 34–37). DEC-205
belongs to the macrophage mannose receptor family of endo-
cytic receptors that include the prototype macrophage mannose
receptor (MMR) (38, 39), phospholipase A2 receptor (PLA2R)
(40, 41) and Endo180 (42, 43). The ectodomain of these recep-
tors contains several domain structures, including a cysteine-
rich domain, fibronectin type II domain, and multiple CRDs (10
for DEC-205 and 8 for others). The MMR, PLA2R, and Endo180
exhibit C-type lectin activity (39, 40, 42), however, the DEC-
205 ligands have yet to be identified. The cytoplasmic domain
of these receptors contains either Tyr-based (in MMR, PLA2R,
and DEC-205) (39, 44, 45), di-aromatic amino acid-based (46),
or di-hydrophobic amino acid-based (in Endo180) (47) motifs to
facilitate their endocytosis to transport cognate ligand intra-
cellularly. Although there are potential Ser and Thr phospho-
rylation sites within the CP of these lectins, no phosphorylation
of these sites has been reported. In addition, the DEC-205 CP
contains a cluster of acidic amino acids (EDE) that targets late
endosomes, where loading of proteolytically processed anti-
genic peptides to major histocompatibility complex class II
occurs (45). DCL-1 is a unique type I transmembrane C-type
lectin in that DCL-1 ectodomain contains only one CRD,
whereas other type I transmembrane C-type lectins contain
more than one domain (e.g. selectins and MMR). DCL-1 CP
contains several putative motifs, including a Tyr-based inter-
nalization, a cluster of acidic amino acids, and Ser and Tyr
phosphorylation motifs, suggesting that DCL-1 CP mediates
not only endocytosis and late endosome targeting but also
signaling.2
The genes encoding DEC-205 (LY75) (17) and DCL-1
(KIAA0022) (22) are juxtaposed within chromosome band 2q24
and are separated by only5.4 kb (Fig. 4). These are independ-
ent genes, because DEC-205 and DCL-1 mRNA are each ex-
pressed independently in hematopoietic cell lines (Fig. 3). The
5-RACE experiment mapped the DCL-1 transcription initia-
tion site at 44 bp upstream of DCL-1 translation start codon
(Fig. 5). Furthermore, our recent luciferase reporter assay
studies showed that both 5-proximal promoters of DEC-205
and DCL-1 have independent promoter activity (data not
shown). The DEC-205 promoter may drive the cotranscription
of the DEC-205 and DCL-1 genes to produce the 9.5-kb DEC-
205/DCL-1 fusion mRNA. This would result from leaky termi-
nation of DEC-205 transcription, a mechanism suggested to
explain the cotranscription of galactose-1-phosphate uridylyl-
transferase and interleukin-11 receptor genes (30). However,
this seems unlikely, because the expression of DEC-205 mRNA
did not correlate to that of DEC-205/DCL-1 fusion mRNA.
Interestingly, all HRS cell lines tested expressed the 9.5-kb
DEC-205/DCL-1 fusion mRNA, but not 4.2-kb DCL-1 mRNA,
whereas other myeloid and B cell lines expressed 7.5-kb DEC-
205 and/or 4.2-kb DCL-1 mRNA (Fig. 3), suggesting that ex-
pression of DEC-205/DCL-1 fusion mRNA is highly regulated.
It is intriguing to speculate that HRS cell lines express certain
transcription factors that may control cotranscription of DEC-
205 and DCL-1 genes.
At mRNA levels, we identified two DEC-205/DCL-1 fusion
mRNA variants (V34-2 and V33-2) different by the presence of
the DEC-205 exon 34. The deletion of exon 34 appears to be the
only alternative splicing that occurs naturally in DEC-205 gene
transcription (Fig. 2). The fusion junctions in the V34-2 and
V33-2 DEC-205/DCL-1 fusion mRNA are in-frame, suggesting
both transcripts are translated.
What would be the functional difference between DEC-205
and DEC-205/DCL-1 fusion protein? Because the fusion protein
contains DCL-1 CP, not DEC-205 CP, it is conceivable that
DEC-205 ligand (currently unknown) to DEC-205/DCL-1 fu-
sion protein would induce distinct signals from that binding to
DEC-205. Further study of DEC-205 and DCL-1 is required to
elucidate the function of these two C-type lectin receptors as
well as DEC-205/DCL-1 fusion protein.
In this study, we used three independent HRS cell lines
(L428, HDLM-2, and KM-H2) and showed that DEC-205/
DCL-1 fusion mRNA is predominantly expressed in these HRS
cell lines (Fig. 3) and that the mRNA is translated into a
DEC-205/DCL-1 fusion protein (Fig. 5). We are currently in-
vestigating the presence of DEC-205/DCL-1 fusion mRNA in
HL-affected lymph nodes in situ. If the expression of DEC-205/
DCL-1 fusion protein is confirmed in vivo in HL, then the
fusion protein may become relevant as a new target for anti-
body or T cell mediated immunotherapy for HL.
FIG. 6. DEC-205/DCL-1 fusion mRNA is translated to the fusion
protein. A, the cell lysates from HRS cell lines (L428, HDLM-2, and
KM-H2), HEL cells, and Jurkat cells were immunoprecipitated with
anti-DEC-205 CP, anti-DCL-1 CP peptide antisera, or non-immune
rabbit IgG, and the immune complexes were subjected to Western blot
analysis using DEC-205 mAbs (MMRI-7 plus M335). The signals were
detected by ECL on x-ray films. B, the cell lysates as above were applied
to an ELISA plate coated with DEC-205 mAbs, and bound DEC-205
(closed circles) or DEC-205/DCL-1 fusion protein (open diamonds) was
detected with anti-DEC-205 CP (for DEC-205) or anti-DCL-1 CP (for
DCL-1), respectively. The signals were detected with O-phenylenedia-
mine dihydrochloride at 492 nm.
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